Investigations

GRABAR LAW OFFICE INVESTIGATES CLAIMS AGAINST OFFICERS OF WEST PHARMACEUTICAL SERVICES, INC. (NYSE: WST)

West Pharmaceutical Services, Inc. (NYSE: WST) is a medical supplies company that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries.

An underlying class action complaint alleges that, West, via certain of its officers, failed to disclose that: (a) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products portfolio; (b) West’s SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company’s profit margins due to operational inefficiencies; (c) these margin pressures created the risk of costly restructuring activities, including the Company’s exit from continuous glucose monitoring contracts with long-standing customers; and (d) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis.

As alleged in the underlying class action complaint, the truth about the fraud was revealed with a series of disclosures culminating on February 13, 2025, when West issued extremely weak 2025 revenue and earnings forecasts. West attributed the disappointing guidance in part to contract manufacturing headwinds, including the loss of two major continuing glucose monitoring customers that had begun transitioning to in-house manufacturing of next-generation devices after West “made the decision to not participate going forward as our financial thresholds cannot be achieved.” West also revealed that its SmartDose wearable injector devices would be “margin-dilutive” in 2025 and that it would be “taking steps to improve [its SmartDose] economics, and all options are on the table.” On this news, West’s stock dropped $123.17 per share, a decline of 38 percent, to close at $199.11 on February 13, 2025.

Current West shareholders who have continuously held West stock since prior to February 16, 2023, can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to them.

If you would like to learn more about this matter at no cost to you, you are encouraged to contact Joshua H. Grabar at [email protected], or call 267-507-6085.

Please enter your name.
Please enter a valid phone number.
Please enter a message.
Send

                                                                                           Attorney Advertising Disclaimer

Standard Derivative Form Retainer

Standard Form Derivative Retainer Letter - No Cost

  • Join This Action

  • Alternatively, you may upload your transactions using the upload button below or email them to [email protected]. *

  • Drop files here or
    Max. file size: 100 MB.
    • Clear Signature
      Signed pursuant to California Civil Code Section 1633.1, et seq. and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

    • Date of signing: *

    • MM slash DD slash YYYY
    • This field is for validation purposes and should be left unchanged.